Kinesis Pharma Launches Alliance4U initiative

FlandersBio's picture
Printer-friendly versionPrinter-friendly version


Kinesis Pharma, a leading partner in drug development that integrates Chemistry, Manufacturing & Control, preclinical, clinical, regulatory, quality and Project Management, is pleased to announce the start of Alliance4U. This new collaborative initiative focuses on adding value to academic start ups, spin offs and small biotech companies by moving drug candidates forward to the next stage in development.

The initiative comprises 3 types of projects: Target Product Profile, Gap Analysis and Drug Development Plan. Kinesis offers to bridge financial and other business challenges to help companies moving to the next phase. Kinesis invites startups, spin off companies and small biotech to apply for this collaborative initiative and benefit from access to a team of experienced professionals with regulatory and industry experience.

Kees Groen, CEO Kinesis Pharma: The combined expertise within Kinesis will be a valuable source for biotech companies to upgrade the quality of their business proposals to potential investors. Early feed-back on this initiative has been extremely positive.

Please click here to read more about the Alliance 4U initiative and send your request to

Copy this html code to your website/blog to embed this press release.


Post new comment

11 + 7 =

To prevent automated spam submissions leave this field empty.
Page execution time was 526.81 ms.

Memory usage:

Memory used at: devel_init()=2.13 MB, devel_shutdown()=22.42 MB.